<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <p class="gem-c-title__context">
      Guidance
    </p>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Licensing of biological products: biosimilars, ATMPs and PMFs in a no-deal Brexit
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph ">
    This guidance sets out the procedures that the MHRA will introduce to regulate biological medicines in the event of no-deal Brexit.
  </p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 18 March 2019
    <br></br>Last updated 8 August 2019
      — <a href="#history">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>




<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav role="navigation" class="gem-c-contents-list gem-c-contents-list--no-underline " data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#guidance-for-uk-marketing-authorisation-applications-for-similar-biological-products-biosimilars-post-brexit" data-track-options="{"dimension29":"Guidance for UK Marketing Authorisation Applications for similar biological products (biosimilars) post Brexit"}" href="#guidance-for-uk-marketing-authorisation-applications-for-similar-biological-products-biosimilars-post-brexit">Guidance for UK Marketing Authorisation Applications for similar biological products (biosimilars) post Brexit</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#guidance-for-uk-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-after-brexit" data-track-options="{"dimension29":"Guidance for UK Marketing Authorisation Applications for Advanced Therapy Medicinal Products (ATMPs) after Brexit"}" href="#guidance-for-uk-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-after-brexit">Guidance for UK Marketing Authorisation Applications for Advanced Therapy Medicinal Products (ATMPs) after Brexit</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-after-brexit" data-track-options="{"dimension29":"Guidance for Plasma Master Files (PMFs) and Vaccine Antigen Master Files (VAMFs) after Brexit"}" href="#guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-after-brexit">Guidance for Plasma Master Files (PMFs) and Vaccine Antigen Master Files (VAMFs) after Brexit</a>
        </li>
    </ol>
  </nav>

      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="guidance-for-uk-marketing-authorisation-applications-for-similar-biological-products-biosimilars-post-brexit">Guidance for UK Marketing Authorisation Applications for similar biological products (biosimilars) post Brexit</h2>

<p>If the UK leaves the <abbr title="European Union">EU</abbr> without a deal, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will continue to regulate biosimilar products according to the same principles that are applicable now. These are covered in regulation 58 of The Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019 amending Reg 53 of The Human Medicines Regulations 2012.</p>

<p>New applications will be assessed at national level and should be submitted using existing procedures for national applications.</p>

<p>Applications for biosimilar products will also be eligible for <a href="https://www.gov.uk/guidance/guidance-note-on-new-assessment-routes-in-a-no-deal-scenario">the targeted assessment procedure</a> after a final opinion from the European Medicines Agency (<abbr title="European Medicines Agency">EMA</abbr>) Committee for Medicinal Products for Human Use (<abbr title="Committee for Medicinal Products for Human Use">CHMP</abbr>) has been obtained.</p>

<p>For biosimilar applications submitted after exit day, the application can only be made with reference to a product that complies with regulation 48 of the Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019.</p>

<p>These will include products that are authorised, or have been authorised for at least 8 years in the UK and those authorised by conversion from <abbr title="European Union">EU</abbr> Marketing Authorisations (<abbr title="Marketing Authorisation">MA</abbr>). It also includes products for which an <abbr title="European Union">EU</abbr> marketing authorisation was in force on exit day but which did not convert into UK marketing authorisations as the holder opted out of that process.</p>

<p>Data and market exclusivity period entitlements for reference medicinal products approved before the date of UK exit from the <abbr title="European Union">EU</abbr> will continue to be applicable in the UK.</p>

<p>As part of the supporting data package, the UK will continue to accept data generated on reference product sourced in accordance with the <a rel="external" href="https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-biosimilar">‘Guideline on similar biological medicinal products <abbr title="Committee for Medicinal Products for Human Use">CHMP</abbr>/437/04 Rev1’</a>.</p>

<p>We have <a href="https://www.gov.uk/drug-safety-update/biosimilar-products">more information about biosimilar products on our website</a>.</p>

<h2 id="guidance-for-uk-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-after-brexit">Guidance for UK Marketing Authorisation Applications for Advanced Therapy Medicinal Products (<abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr>) after Brexit</h2>

<p>If the UK leaves the <abbr title="European Union">EU</abbr> without a deal, <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will be regulated nationally by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> according to the same principles that previously applied. These principles are covered in regulation 4 of The Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019 (SI 2019/XXXX); Reg 2A of The Human Medicines Regulations 2012 (SI 2012/1916) as amended).</p>

<p>This means that marketing authorisation applications for <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will be assessed in accordance with the general provisions in place for the licensing of medicines, taking the specific requirements for this group of medicines into account.</p>

<p>Data, traceability, exemptions from licensing, packaging and post-authorisation requirements will remain unchanged from the current <abbr title="European Union">EU</abbr> requirements and will be transposed into UK law.</p>

<p>Definitions of individual classes of <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will remain unchanged and classification of <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> in the UK will be undertaken by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> <a rel="external" href="https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf">in accordance with the legislation and current guidance</a>.</p>

<p>Accordingly, <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will continue to be classified into either:</p>

<ul>
  <li>gene therapy medicinal products</li>
  <li>somatic cell therapy medicinal products</li>
  <li>tissue engineered products</li>
</ul>

<h3 id="what-to-do-if-you-are-uncertain-about-classification">What to do if you are uncertain about classification</h3>

<p>If you are uncertain about the classification of your product fill out the <a rel="external" href="https://info.mhra.gov.uk/forms/atmp_form.aspx"><abbr title="Advanced Therapy Medicinal Product">ATMP</abbr> advice form</a> or consult the <a rel="external" href="https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf">Reflection paper on classification of advanced therapy medicinal products (<abbr title="European Medicines Agency">EMA</abbr>/CAT/600280/2010 rev.1)</a>.</p>

<h2 id="guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-after-brexit">Guidance for Plasma Master Files (<abbr title="Plasma Master Files">PMFs</abbr>) and Vaccine Antigen Master Files (<abbr title="Vaccine Antigen Master Files">VAMFs</abbr>) after Brexit</h2>

<p>If the UK leaves the <abbr title="European Union">EU</abbr> without a deal, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will continue to recognise the existing <abbr title="Plasma Master File">PMF</abbr> and associated inspections until further notice.</p>

<p>The supervision of the <abbr title="Plasma Master Files">PMFs</abbr> may eventually be fully transferred into a national system. This will be communicated by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> at a later date. In the interim, we require the <abbr title="Plasma Master File">PMF</abbr> holder to notify the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> of the outcome of the annual updates within 4 weeks of the completion of the update.</p>

<p>For variation applications submitted to the <abbr title="European Medicines Agency">EMA</abbr>, the <abbr title="Plasma Master File">PMF</abbr> holder must notify the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> of the submission and determination outcome of such an application within 4 weeks of the submission and determination dates, respectively.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> reserve the right for further review where an <abbr title="European Union">EU</abbr> assessment report is deemed to indicate significant public health issues that are insufficiently addressed at European level.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will issue guidance on the transfer of <abbr title="Plasma Master Files">PMFs</abbr> to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> database when this becomes relevant, but the data requirements will be in accordance with those currently in place in the <abbr title="European Union">EU</abbr>.</p>

<p>No <abbr title="Vaccine Antigen Master File">VAMF</abbr> is in use in the UK at present. Applicants proposing such a submission, which will be subject to the same standards and criteria as apply now, should contact the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> for further guidance.</p>

<p>This guidance will apply from exit day in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

<div class="call-to-action">
<h3 id="stay-up-to-date">Stay up to date</h3>

<p>This page tells you what to do if you the UK leaves the <abbr title="European Union">EU</abbr> without a deal. It will be updated if anything changes, including if a deal is agreed.</p>

<p><a href="https://www.gov.uk/email-signup/?topic=/government/brexit">Sign up to email alerts</a> to get the latest information.</p>
</div>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 18 March 2019
    <br></br>Last updated 8 August 2019
      <a href="#full-history" class="app-c-published-dates__toggle" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-08-08T14:58:49.000+01:00">8 August 2019</time>
              Updated information to make action to take clearer and removed some outdated background information.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-03-18T15:46:00.000+00:00">18 March 2019</time>
              First published.
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">

    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-ebade8f8" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-ebade8f8" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/find-eu-exit-guidance-business" data-track-options="{"dimension28":"1","dimension29":"Find Brexit guidance for your business"}" href="/find-eu-exit-guidance-business">Find Brexit guidance for your business</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-ebade8f8" data-module="gem-toggle">

    <h3 id="related-nav-collections-ebade8f8" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario" data-track-options="{"dimension28":"1","dimension29":"MHRA guidance and publications about a possible no deal Brexit"}" href="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario">MHRA guidance and publications about a possible no deal Brexit</a></li>

  </ul>
</nav>

  </div>


</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-c03bd74e" data-module="gem-toggle">

    <h2 id="related-nav-topics-c03bd74e" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines" data-track-options="{"dimension28":"2","dimension29":"Manufacturing, wholesaling, importing and exporting medicines"}" href="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines">Manufacturing, wholesaling, importing and exporting medicines</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"2","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>